Percorrer por autor "Teixeira, Paulo"
A mostrar 1 - 4 de 4
Resultados por página
Opções de ordenação
- Protocolo de Avaliação Orofacial: revisão e validação da versão 2 (PAOF-2) em crianças dos quatro aos nove anosPublication . Guimarães, Isabel; Teixeira, Paulo; Raimundo, Ana Filipa; Miguel, Susana; Nobre, Helena; Ascensão, MarianaObjetivos: Descrever o processo de revisão do protocolo de avaliação orofacial (PAOF) e determinar a praticabilidade, fidedignidade e validade da segunda versão (PAOF-2). Métodos: Estudo metodológico, observacional e transversal que envolveu duas fases, revisão e validação. A fase de revisão incluiu a análise dos conteúdos do PAOF (dimensões, itens, escala de avaliação e forma de registo) seguido de validação de conteúdo em grupo focal e pré-teste. Na fase de validação, o PAOF-2 foi aplicado, por terapeutas da fala, a crianças com idades entre os quatro e os nove anos. Foram analisadas as propriedades clinimétricas de praticabilidade (tempo de aplicação), fidedignidade (consistência interna e acordo intra- e inter-examinadores) e validade (construto, convergente e discriminativa). Resultados: A revisão resultou num instrumento com duas dimensões ‘Estrutura’ e ‘Mobilidade’, 47 itens, escala de cinco pontos e folha de registo. A validade de conteúdo do PAOF foi analisada por 13 terapeutas da fala. A validação realizada em 312 crianças indicou praticabilidade adequada (15 minutos de tempo médio de aplicação), consistência interna excelente a boa (Alfa de Cronbach entre 0,94 e 0,77), excelente fidedignidade intra- e inter-examinadores (Coeficiente de correlação intraclasse >0,75), validade de construto (a análise fatorial exploratória explica 71,4% da estrutura interna do PAOF-2 com 47 itens), boa a moderada validade convergente entre o PAOF-2 e o original e validade discriminativa na dimensão ‘Mobilidade’ de acordo com a idade. Conclusão: O PAOF-2 é um instrumento prático, fidedigno e válido com potencialidade para instrumento de avaliação orofacial de crianças entre os quatro e os nove anos de idade.
- Protocolo de avaliação orofacial: um contributo para a sua revisão e validaçãoPublication . Teixeira, Paulo; Guimarães, Isabel
- The role of the gut microbiome in clinical outcomes of colorectal cancer: a systematic review (2020–2025)Publication . Santos, Iara; Liberal, Joana; Teixeira, Paulo; Martins, Diana; Mendes, FernandoABSTRACT: Background: The Colorectal Cancer (CRC) pathogenesis and therapeutic efficacy are influenced by the gut microbiome, making it a promising biomarker for predicting treatment responses and adverse effects. This systematic review aims to outline the gut microbiome composition in individuals with CRC undergoing the same therapeutic regimen and evaluate interindividual microbiome profile variations to better understand how these differences may influence therapeutic outcomes. Methods: Key studies investigating the microbiome’s role in therapeutic approaches for CRC were searched in both PubMed and Cochrane databases on 12 and 22 March 2025, respectively. Eligible studies included free full-text English-language randomized clinical trials and human observational studies reporting on gut microbiome composition and treatment outcomes. RoB 2 and ROBINS-I were employed in the evaluation of bias for randomized trials and observational studies, respectively. Data extracted was narratively analyzed. Results: Six studies involving a total of 361 individuals were included. Therapeutic interventions, either standard treatments and/or those targeting the gut microbiome, generally increased probiotic taxa and reduced pro-carcinogenic bacteria. However, no consistent pattern of improved clinical outcomes was observed, suggesting that treatment mechanisms, the tumor’s nature, and individual characteristics play critical roles in microbiome modulation. Conclusion: The gut microbiome holds significant potential in clinical settings. Nonetheless, further research is needed to better understand its functional aspects and to consider the influence of treatment mechanisms, the tumor’s nature, and individual characteristics as modulators, in order to optimize clinical outcomes
- Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticinePublication . Tesarova, Barbora; Dostalova, Simona; Smidova, Veronika; Goliasova, Zita; Skubalova, Zuzana; Michalkova, Hana; Hynek, David; Michalek, Petr; Polanska, Hana; Vaculovicova, Marketa; Hacek, Jaromir; Eckschlager, Tomas; Stiborova, Marie; Pires, Ana S.; Neves, Ana R.M.; Abrantes, Ana M; Rodrigues, Tiago; Matafome, Paulo; Botelho, Maria F.; Teixeira, Paulo; Mendes, Fernando 1973 -; Heger, ZbynekSurface functionalisations substantially influence the performance of drug delivery vehicles by improving their biocompatibility, selectivity and circulation in bloodstream. Herein, we present the study of in vitro and in vivo behaviour of a highly potent cytostatic alkaloid ellipticine (Elli) encapsulated in internal cavity of ferritin (FRT)-based nanocarrier (hereinafter referred to as FRTElli). In addition, FRTElli surface was functionalised with three different molecular coatings: two types of protective PAS peptides (10- or 20-residues lengths) with sequences comprising amino acids proline (P), alanine (A) and serine (S) (to form PAS-10-FRTElli or PAS-20-FRTElli, respectively), or polyethylene glycol (PEG-FRTElli). All three surface modifications of FRT disposed sufficient encapsulation efficiency of Elli with no premature cumulative release of cargo. Noteworthy, all tested surface modifications displayed beneficial effects on the in vitro biocompatibility. PAS-10-FRTElli exhibited markedly reduced uptake by macrophages compared to PAS-20-FRTElli, PEG-FRTElli or unmodified FRTElli. The exceptional properties of PAS-10-FRTElli were validated by an array of in vitro analyses including formation of protein corona, uptake efficiency or screenings of selectivity of cytotoxicity. In murine preclinical model bearing triple-negative breast cancer (MDA-MB-231) xenograft, compared to free Elli or FRTElli, PAS-10-FRTElli displayed enhanced accumulation of Elli within tumour tissue, while hampering the uptake of Elli into off-target tissues. Noteworthy, PAS-10-FRTElli led to decreased in vivo complement (C3) activation and protein corona formation. Taken together, presented in vivo results indicate that PAS-10-FRTElli represents a promising stealth platform for translation into clinical settings.